Industries de la santé
GLP-1 Receptor Agonists and SGLT-2 Inhibitors exceed $8bn in combined sales across the seven major markets in 2017
13 Mars 2018
During 2017, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter -2 (SGLT-2) inhibitors marketed across the seven major markets (7MM*) brought in more than $8bn in combined sales, observes GlobalData, a leading data and analytics company. Both T2D drug classes continue to gain substantial market share through the glycemic and non-glycemic benefits (e.g. CV... |Plus d'articles...
- To help eradicate neglected tropical diseases, pharma must juggle ROI concerns and social responsibility
- Vif intérêt de la communauté scientifique pour le monitoring des biothérapies lors du congrès ECCO
- SuperSonic Imagine présente Aixplorer® Ultimate lors du Congrès Européen de Radiologie, ECR 2018
- Guerbet présentera ses offres intégrées incluant Contrast&Care®, nouvelle application de gestion des injections des produits de contraste, lors de l'European Congress of Radiology (ECR) 2018